Clinical Trial Update: Folfox+Irinotecan+Chemort In Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a FOLFOX plus Irinotecan regimen with chemotherapy for gastroesophageal junction adenocarcinoma and esophagogastric cancer is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Chemort
• FOLFOX regimen (folinic acid (leucovorin) + fluorouracil + oxaliplatin)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer | Phase 2 | Status: RECRUITING